Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | TLR4 | O00206 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19215696 | 0.84 | TLR4 (0.36) | ALDH1A1NPC1RAB9APTPN1MAPT | |
| SCHEMBL11527220 | 0.81 | THRB (0.39) | ALDH1A1NPC1RAB9ALMNAPTPN1 | |
| SCHEMBL9106968 | 0.79 | FOLH1 (0.40) | LMNAMEN1KMT2A | |
| SCHEMBL1830401 | 0.78 | CYP1A2 (0.42) | ALDH1A1PTPN1MEN1KMT2ATLR4 | |
| SCHEMBL16093787 | 0.77 | ALDH1A1 (0.33) | ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL10248671 | 0.76 | — | — | |
| SCHEMBL10616701 | 0.75 | — | — | |
| SCHEMBL22328939 | 0.74 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL11854232 | 0.74 | MAPT (0.32) | MAPTMEN1KMT2ABRD4 | |
| SCHEMBL3628059 | 0.74 | CHRM5 (0.42) | ALDH1A1NPC1RAB9ALMNAPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753433-B2 | Methods of synthesizing substituted purine compounds | Epizyme, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20180134745-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS | Epizyme, Inc. | 2018-05-17 | — | — | US | disclosed |
| US-9738679-B2 | Methods of synthesizing substituted purine compounds | Epizyme, Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160024134-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS | Epizyme, Inc. | 2016-01-28 | — | — | US | disclosed |
| US-20150366893-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | Epizyme, Inc. (US) | 2015-12-24 | — | — | US | disclosed |
| US-9096634-B2 | Substituted purine and 7-deazapurine compounds | Epizyme, Inc. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140051654-A1 | Substituted Purine and 7-Deazapurine Compounds | Epizyme, Inc. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8580762-B2 | Substituted purine and 7-deazapurine compounds | Epizyme, Inc. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120142625-A1 | Substituted Purine And 7-Deazapurine Compounds | Epizyme, Inc. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024134-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS | DOT1L, MECP2, TDP1 | ALDH1A1 652/4885NPC1 2258/4885RAB9A 2079/4885 |
| US-11753433-B2 | Methods of synthesizing substituted purine compounds | DOT1L, MECP2, TDP1 | ALDH1A1 652/4885NPC1 2258/4885RAB9A 2079/4885 |
| US-20180134745-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS | DOT1L, MECP2, TDP1 | ALDH1A1 652/4885NPC1 2258/4885RAB9A 2079/4885 |
| US-20150366893-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | TPMT, DIMT1, DAZAP1 | ALDH1A1 592/4885NPC1 1157/4885RAB9A 2031/4885 |
| US-20140051654-A1 | Substituted Purine and 7-Deazapurine Compounds | TPMT, DIMT1, DAZAP1 | ALDH1A1 592/4885NPC1 1157/4885RAB9A 2031/4885 |
| US-20120142625-A1 | Substituted Purine And 7-Deazapurine Compounds | TPMT, DIMT1, DAZAP1 | ALDH1A1 592/4885NPC1 1157/4885RAB9A 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.